Top Markets
#1 Akedo Akedo +63.33%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.58%
#4 Cross Cross +34.01%
#5 Black Phoenix Black Phoenix +33.94%
#6 Cap Cap +32.66%
#7 Velvet Velvet +25.73%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.06%
#9 Ravencoin Ravencoin +13.84%
#10 DoubleZero DoubleZero +13.55%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Valion Bio, Inc. Valion Bio, Inc.

Valion Bio, Inc.

VBIO
Clasificación en acciones #38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Precio por acción
$0.1645
Capitalización bursátil
$681.26K
Cambio (1 día)
-3.69%
Cambio (1 año)
-95.30%
País
US
Comercio Valion Bio, Inc. (VBIO)

Categoría

Healthcare
Ganancias de Valion Bio, Inc. (VBIO)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Valion Bio, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Valion Bio, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE